Sensorion (FR0012596468 – ALSEN) a biopharmaceutical company that specializes in the development of novel therapies to restore, treat, and prevent inner ear diseases such as hearing loss, tinnitus, and vertigo, announced that the European Medicines Agency (EMA) has accepted its Pediatric Investigation Plan (PIP) for both development in the treatment of severe hearing loss and for prevention of ototoxicity caused by cisplatin (CIO) in the pediatric population.
“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients,” said Nawal Ouzren, Sensorion CEO. “Indeed, this approval will allow Sensorion to develop SENS-401 for pediatric patients suffering from severe hearing loss but also in the prevention of ototoxicity caused by cisplatin. The loss of hearing in pediatric oncology patients often generates a lifelong handicap and is one of the main side effects of chemotherapy. We think that SENS-401 could be a safe and effective treatment for these severe lesions, a field in which there are substantial unmet medical needs. So we intend to continue discussions and propose a Phase 2 clinical trial protocol in order to investigate SENS-401 in this indication.”
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL). Sensorion initiated Phase 2 clinical trial in this indication at the start of 2019. The interim safety results are expected at the end of 2019. In November 2016, SENS-401 already received the orphan drug designation in Europe in SSNHL.